Recently, Ahn et al. reported that the combination of osimertinib and durvalumab was not appropriate for patients with advanced EGFR mutation‐positive NSCLC due to the increased incidence of interstitial lung disease (ILD).3 Although only 34 patients were treated with this combination therapy in their study, ILD was observed in 38% of all patients and 60% of Japanese patients.3 Moreover, a recent study described an increased incidence of ILD in patients who received osimertinib immediately after nivolumab, an anti‐PD‐1 antibody.4, 5. Here, EGFR is linked to interstitial lung disease.